Company news
Cg Oncology, Inc. (NASDAQ:CGON) news
Cg Oncology, Inc. news releases on 6ix. Latest, Sep 2, 2026: CG Oncology to Present at Upcoming Investor Conferences in September
Press releases & updates
CG Oncology to Present at Upcoming Investor Conferences in September
September 2, 2026
CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 6, 2026
CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology
July 27, 2026
CG Oncology to Present at Upcoming Investor Conferences in June
May 28, 2026
SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
May 18, 2026
CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
May 15, 2026
CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC
May 11, 2026
CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates
May 8, 2026
CG Oncology to Present at Upcoming Investor Conferences in May
May 5, 2026
CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates
February 27, 2026
CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference
February 22, 2026
Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics
January 14, 2026
CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC
January 9, 2026
CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
December 17, 2025
New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer
December 4, 2025
CG Oncology Announces New Board Member and Board Transition
November 25, 2025
CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 13, 2025
CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months
September 4, 2025
CG Oncology Completes Enrollment in PIVOT-006
September 2, 2025
CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences
August 28, 2025
CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 7, 2025
Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals
July 28, 2025
Lustgarten Foundation Appoints Arthur Kuan, MS, to Board of Directors
July 1, 2025
CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
June 4, 2025
CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference
May 14, 2025
CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
May 12, 2025
SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
April 30, 2025
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
April 25, 2025
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025
April 23, 2025
CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates
March 30, 2025
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates
March 27, 2025
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
March 23, 2025
CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates
March 11, 2025
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference
February 25, 2025
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 15, 2024
CG Oncology Announces Pricing of Public Offering
December 11, 2024
CG Oncology Announces Proposed Public Offering
December 10, 2024
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
December 5, 2024
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
December 4, 2024
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024
December 1, 2024
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
November 19, 2024
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 11, 2024
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
November 10, 2024
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 29, 2024
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 7, 2024
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
June 17, 2024
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
June 5, 2024
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
May 23, 2024
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
May 8, 2024